Profiling the proteome dynamics during the cell cycle of human hepatoma cells

Proteomics

Volumn 8, Issue 14, 2008, Pages 2872-2884

  Hsieh, Sen Yung ^a,b   Zhuang, Feng Hui ^a   Wu, Yi Ting ^a,c   Chen, Jen Kun ^a,c   Lee, Yun Lin ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Cell cycle; Hepatoma; Proteome dynamics; Systems biology

Indexed keywords

MYC PROTEIN; PROTEIN C JUN; PROTEIN P53; TRANSCRIPTION FACTOR YY1;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; HEPATOMA CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEOMICS; VALIDATION PROCESS;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CLUSTER ANALYSIS; CYTOSKELETON; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; PROTEIN ISOFORMS; PROTEOME; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 48949091027     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800196     Document Type: Article

References (51)

1. Hanahan, D., Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100, 57-70.
2. Sharpless, N. E., DePinho, R. A., Telomeres, stem cells, senescence, and cancer. J. Clin. Invest. 2004, 113, 160-168.
3. Vogelstein, B., Kinzler, K. W., Cancer genes and the pathways they control. Nat. Med. 2004, 10, 789-799.
4. Flory, M. R., Lee, H., Bonneau, R., Mallick, P. et al., Quantitative proteomic analysis of the budding yeast cell cycle using acid-cleavable isotope-coded affinity tag reagents. Proteomics 2006, 6, 6146-6157.
5. Hanash, S., Disease proteomics. Nature 2003, 422, 226-232.
6. Hsieh, S. Y., Liaw, S. F., Lee, S. N., Hsieh, P. S. et al., Aberrant caspase-activated DNase (CAD) transcripts in human hepatoma cells. Br. J. Cancer 2003, 88, 210-216.
7. Schorl, C., Sedivy, J. M., Analysis of cell cycle phases and progression in cultured mammalian cells. Methods 2007, 41, 143-150.
8. Hsieh, S. Y., Shih, T. C., Yeh, C. Y., Lin, C. J. et al., Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006, 6, 5322-5331.
9. Honda, M., Yamashita, T., Ueda, T., Takatori, H. et al., Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 2006, 44, 1122-1138.
10. Steel, L. F., Haab, B. B., Hanash, S. M., Methods of comparative proteomic profiling for disease diagnostics. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2005, 815, 275-284.
11. Reed, S. I., The ubiquitin-proteasome pathway in cell cycle control. Results Probl. Cell Differ. 2006, 42, 147-181.
12. Reinstein, E., Ciechanover, A., Narrative review: Protein degradation and human diseases: The ubiquitin connection. Ann. Intern. Med. 2006, 145, 676-684.
13. Roberts, L. R., Gores, G. J., Emerging drugs for hepatocellular carcinoma. Expert. Opin. Emerg. Drugs 2006, 11, 469-487.
14. Konstantinopoulos, P. A., Papavassiliou, A. G., The potential of proteasome inhibition in the treatment of colon cancer. Expert Opin. Investig. Drugs 2006, 15, 1067-1075.
15. Kerr, L. E., Birse-Archbold, J. L., Short, D. M., McGregor, A. L. et al., Nucleophosmin is a novel Bax chaperone that regulates apoptotic cell death. Oncogene 2007, 26, 2554-2562.
16. Wang, B., Liu, K., Lin, F. T., Lin, W. C., A role for 14-3-3 tau in E2F1 stabilization and DNA damage-induced apoptosis. J. Biol. Chem. 2004, 279, 54140-54152.
17. Wang, S., Zhang, B., Faller, D. V., Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J. 2002, 21, 3019-3028.
18. van den Heuvel, A. P., de Vries-Smits, A. M., van Weeren, P. C., Dijkers, P. F. et al., Binding of protein kinase B to the plakin family member periplakin. J. Cell Sci. 2002, 115, 3957-3966.
19. Karashima, T., Watt, F. M., Interaction of periplakin and envoplakin with intermediate filaments. J. Cell Sci. 2002, 115, 5027-5037.
20. Kazerounian, S., Uitto, J., Aho, S., Unique role for the periplakin tail in intermediate filament association: Specific binding to keratin 8 and vimentin. Exp. Dermatol. 2002, 11, 428-438.
21. Waterman, M. J., Stavridi, E. S., Waterman, J. L., Halazonetis, T. D., ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genetics 2998, 19, 175-178.
22. Jin, Y., Dai, M. S., Lu, S. Z., Xu, Y. et al., 14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation. EMBO J. 2006, 25, 1207-1218.
23. Lebron, C., Chen, L., Gilkes, D. M., Chen, J., Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 2006, 25, 1196-1206.
24. Shan, Y. X., Liu, T. J., Su, H. F., Samsamshariat, A. et al., Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J. Mol. Cell Cardiol. 2003, 35, 1135-1143.
25. Stilo, R., Liguoro, D., di Jeso, B., Leonardi, A., Vito, P., The alpha-chain of the nascent polypeptide-associated complex binds to and regulates FADD function. Biochem. Biophys. Res. Commun. 2003, 303, 1034-1041.
26. Katayama, H., Sasai, K., Kawai, H., Yuan, Z. M. et al., Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genetics 2004, 36, 55-62.
27. Gatz, S. A., Wiesmuller, L., p53 in recombination and repair. Cell Death Differ. 2006, 13, 1003-1010.
28. De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, D. U. et al., Induction of gadd45beta by NF-kappaB downregulates proapoptotic JNK signalling. Nature 2001, 414, 308-313.
29. Papa, S., Zazzeroni, F., Bubici, C., Jayawardena, S. et al., Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat. Cell Biol. 2004, 6, 146-153.
30. Mamidipudi, V., Dhillon, N. K., Parman, T., Miller, L. D. et al., RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints. Oncogene 2007, 26, 2914-2924.
31. Lopez-Bergami, P., Habelhah, H., Bhoumik, A., Zhang, W. et al., RACK1 mediates activation of JNK by protein kinase C. Mol. Cell 2005, 19, 309-320.
32. Zhang, W., Zong, C. S., Hermanto, U., Lopez-Bergami, P. et al., RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage- independent growth. Mol. Cell Biol. 2006, 26, 413-424.
33. Berns, H., Humar, R., Hengerer, B., Kiefer, F. N., Battegay, E. J., RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J. 2000, 14, 2549-2558.
34. Llorca, O., McCormack, E. A., Hynes, G., Grantham, J. et al., Eukaryotic type II chaperonin CCT interacts with actin through specific subunits. Nature 1999, 402, 693-696.
35. Martin-Benito, J., Grantham, J., Boskovic, J., Brackley, K. I. et al., The inter-ring arrangement of the cytosolic chaperonin CCT. EMBO Rep. 2007, 8, 252-257.
36. Grantham, J., Brackley, K. I., Willison, K. R., Substantial CCT activity is required for cell cycle progression and cytoskeletal organization in mammalian cells. Exp. Cell Res. 2006, 312, 2309-2324.
37. Camasses, A., Bogdanova, A., Shevchenko, A., Zachariae, W., The CCT chaperonin promotes activation of the anaphase-promoting complex through the generation of functional Cdc20. Mol. Cell 2003, 12, 87-100.
38. Yokota, S., Yanagi, H., Yura, T., Kubota, H., Cytosolic chaperonin is up-regulated during cell growth. Preferential expression and binding to tubulin at G(1)/S transition through early S phase. J. Biol. Chem. 1999, 274, 37070-37078.
39. Yokota, S., Yokota, S., Yamamoto, Y., Shimizu, K. et al., Increased expression of cytosolic chaperonin CCT in human hepatocellular and colonic carcinoma. Cell Stress Chaperones 2001, 6, 345-350.
40. Coghlin, C., Carpenter, B., Dundas, S. R., Lawrie, L. C. et al., Characterization and over-expression of chaperonin t-complex proteins in colorectal cancer. J. Pathol. 2006, 210, 351-357.
41. Aitkenk, A., 14-3-3 proteins: A historic overview. Semin. Cancer Biol. 2006, 16, 162-172.
42. Sekimoto, T., Fukumoto, M., Yoneda, Y., 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27(Kip1). EMBO J. 2004, 23, 1934-1942.
43. Peng, C. Y., Graves, P. R., Thoma, R. S., Wu, Z. et al., Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277, 1501-1505.
44. Dalal, S. N., Yaffe, M. B., DeCaprio, J. A., 14-3-3 family members act coordinately to regulate mitotic progression. Cell Cycle 2004, 3, 672-677.
45. Hermeking, H., Benzinger, A., 14-3-3 proteins in cell cycle regulation. Semin. Cancer Biol. 2006, 16, 183-192.
46. Wilker, E., Yaffe, M. B., 14-3-3 Proteins-a focus on cancer and human disease. J Mol. Cell Cardiol. 2004, 37, 633-642.
47. Hermeking, H., The 14-3-3 cancer connection. Nat. Rev. Cancer 2003, 3, 931-943.
48. Grisendi, S., Pandolfi, P. P., Two decades of cancer genetics: From specificity to pleiotropic networks. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 83-91.
49. Semenza, G. L., Development of novel therapeutic strategies that target HIF-1. Expert Opin. Ther. Targets 2006, 10, 267-280.
50. Rozan, L. M., El-Deiry, W. S., p53 downstream target genes and tumor suppression: A classical view in evolution. Cell Death Differ. 2007, 14, 3-9.
51. Joerger, A. C., Fersht, A. R., Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 2007, 26, 2226-2242.